Clinical efficacy of levonorgestrel releasing intrauterine system for the treatment of adenomyosis in perimenopausal women

Abstract

Background: The aim of this study was to evaluate the efficacy of levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of menorrhagia, dysmenorrhea, and poor quality of life caused by adenomyosis in perimenopausal women. Materials and Methods: Ninety-six women with menorrhagia, dysmenorrhea, and poor quality of life with adenomyosis in perimenopausal women were included and were invited to complete a SF-36 Health Survey. Excluded were cervical and endometrial lesions that underwent a Pap smear, transvaginal sonography, and endometrial biopsy. LNG-IUS was inserted in the postmenstrual phase. Blood loss was assessed by pictorial blood loss assessment chart (PBAC), and dysmenorrhea intensity was assessed by a visual analogue scale (VAS). The patients were followed up after one, three, six, 12, and after 18 months. The participations are asked to complete the short form 36 (SF- 36) health survey questionnaires. Results: The menstrual blood size was (60.287±21.832) (41.186±16.153), (30.988±15.670), (19.238±13.649), (16±11.464) after treatment one, three, six, 12, and after 18 months, respectively, which reduced significantly compare with before treatment (88.691±33.775, p < 0.05). The VAS of dysmenorrheal dropped continuously and significantly from the baseline score of (74.968±15.889) to (38.797±16.781), (24.857±16.595), (15.840±14.305), (10.784±13.593), and (8.196±12.919), respectively, after treatment one, three, six, 12, and after 18 months of the LNG-IUS insertion (p < 0.05). The results of SF-36 Health Survey shown the quality of life was significantly improved. Conclusion: These data suggest that LNG-IUS is a safe and effective option for reduces menorrhagia, relieve dysmenorrhea, and improve the quality of life in patients with adenomyosis from perimenopausal women.